Faricimab meets primary endpoint in phase 3 studies
Patients with neovascular or “wet” age-related macular degeneration (nAMD) who received faricimab (Genentech) injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to those receiving aflibercept injections every 8 weeks, according to the results of 2 phase 3 clinical studies.
“These results show the potential of faricimab as a new class of medicine that could extend time between treatments for people living with neovascular age-related macular degeneration,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, in a press release. “We have now seen positive and consistent results in four Phase III studies for faricimab across both neovascular age-related macular degeneration and diabetic macular edema. We look forward to submitting these data to global regulatory authorities, with the aim of bringing this promising treatment option to patients as soon as possible.”
Read the full press release here.